RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer

Preoperative chemotherapy, often using docetaxel and cisplatin, is a famous treatment option for advanced gastric cancer in Japan. But, there are no effective biomarkers that predict the therapeutic outcome on gastric cancer. Ribophorin II (RPN2) silencing, which decreases glycosylation of P-glycopr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Daisuke, Goi, Takanori, Koneri, Kenji, Hirono, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880597/
https://www.ncbi.nlm.nih.gov/pubmed/29632637
http://dx.doi.org/10.18632/oncotarget.24622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880597/
https://www.ncbi.nlm.nih.gov/pubmed/29632637
http://dx.doi.org/10.18632/oncotarget.24622

Ejemplares similares